财务数据关键指标变化 - 2023年全年净亏损9600万美元，摊薄后每股净亏损2.25美元，去年同期净亏损8910万美元，摊薄后每股净亏损3.35美元[7] - 2023年全年经营活动净现金使用量为9220万美元，去年同期为6760万美元[7] - 2023年研发费用为7822.5万美元，去年为6899.3万美元[17] - 2023年一般及行政费用为2378.7万美元，去年为2191万美元[17] - 2023年总资产为1.75546亿美元，去年为1.31435亿美元[19] - 2023年总负债为7386.1万美元，去年为5452.7万美元[19] - 2023年股东权益为1.01685亿美元，去年为7690.8万美元[19] 资金状况 - 截至2023年12月31日，公司现金、现金等价物和有价证券为1.607亿美元[8] - 2024年2月完成A类普通股增发，毛收入约2.875亿美元[8][11] 业务进展 - 关键3期ORIGIN 3试验预计2025年上半年公布topline数据[5][11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Delaware 81-2744449 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission File Number: 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2744449 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) ...

1. One patient with COVID-19 was hospitalized and recovered. 28 © 2023 VERA THERAPEUTICS, INC. Ability to leverage ORIGIN worldwide sites ORIGIN Subgroup Analyses Inform Phase 3 Design to Maximize Competitive Positioning 2020 2023 2024 2025 Phase 2b Trial Ongoing Results Corporate Presentation © 2023 VERA THERAPEUTICS, INC. This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements in this presentation that are not statements of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Delaware | 81-2744449 | | --- | --- | | (State ...

Sean Grant, MBA Chief Financial Officer | --- | --- | --- | --- | --- | |-------|----------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------|-------------------------------------------------| | | Joanne Curley, PhD Chief Development Officer | Lauren Frenz, MBA Chief Business Officer | | Joe Young, CPA, MBA Chief Accounting Officer | | | • >20 years drug dev, former VP project | • 15 years industry expe ...

财务状况 - Vera Therapeutics, Inc.截至2022年9月30日现金、现金等价物和短期投资约为1.34亿美元[8] 主要临床阶段资产 - Vera Therapeutics, Inc.的主要临床阶段资产包括atacicept和anti-BK病毒mAb，分别在IgA肾病和博科病毒感染方面具有潜在疾病修饰作用[5] 管理团队经验 - Vera Therapeutics, Inc.的管理团队拥有丰富的临床和商业经验，包括领导药物开发、全球临床试验执行和财务策略等方面[7] IgAN治疗效果 - Tarpeyo™是首个获批用于IgAN的药物，显示了基线蛋白尿减少约18%至周36时34%的效果[19] - Travere的sparsentan在IgAN中显示出35%的蛋白尿减少[19] - Atacicept在24周时相对安慰剂减少蛋白尿约-18% vs -4%[39] - Atacicept在36周时相对安慰剂减少蛋白尿约-34% vs -5%[39] - Atacicept在24周时相对安慰剂减少Gd-IgA1约-60%[39] - Atacicept在36周时相对安慰剂减少Gd-IgA1数据待公布[39] - Atacicept的安全数据与安慰剂相当[39] - Atacicept 150 mg qwk在第52周的完全肾脏反应率为145/180[58] BK病毒感染 - BK病毒导致移植患者显著的发病率和死亡率[60] - BK病毒感染在肾移植患者和HSCT接受者中有影响[60] - MAU868在第12周对BK病毒血浆病毒载量的中位数DNA拷贝/毫升的对数减少为-1.14[64] - MAU868对BK病毒血浆病毒载量有显著的减少效果[64]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2744449 (State or other ju ...

therapeutics | --- | --- | --- | --- | --- | |------------------------|--------------------------------|-------|-------|-------| | | | | | | | Corporate Presentation | | | | | | September 2022 | C | | | | | | | | | | | | | | | | | | | | | | | | C | | | | | | © 2022 VERA THERAPEUTICS, INC. | | | | Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements in this presentation that are not sta ...